Is Aptevo Therapeutics Inc. (APVO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 46.3% / 30% | 87.2% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 46.3% / 33% | 87.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 29.7% / 33% | 55.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 46.3% / 33% | 87.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 29.7% / 33% | 55.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -242.7% | |
| Return on Assets (ROA) | -79.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$24M |
| Free Cash Flow | -$24M |
| Total Debt | $5M |
| Debt-to-Equity | 27.5 |
| Current Ratio | 4.0 |
| Total Assets | $16M |
Price & Trading
| Last Close | $4.51 |
| 50-Day MA | $6.58 |
| 200-Day MA | $26.91 |
| Avg Volume | 194K |
| Beta | 1.4 |
|
52-Week Range
$3.95
| |
About Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Aptevo Therapeutics Inc. (APVO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Aptevo Therapeutics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Aptevo Therapeutics Inc.'s debt ratio?
Aptevo Therapeutics Inc.'s debt ratio is 46.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 29.7%.
What are Aptevo Therapeutics Inc.'s key financial metrics?
Aptevo Therapeutics Inc. has a market capitalization of $7M. Return on equity stands at -242.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.